DOCSLIB.ORG

August 2020 Asra News.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
August 2020 Asra News.Pdf NEWS A PUBLICATION OF THE AMERICAN SOCIETY OF REGIONAL ANESTHESIA AND PAIN MEDICINE AUGUST 2020 THE LEADERSHIP/MENTORSHIP ISSUE Regional Fellowship What Makes a Great Training - page 7 Leader? - page 16 The Beauty of Diversity What Showing Up Can in Medicine - page 10 Do for You - page 23 Advancing the science and practice of regional anesthesiology and pain medicine to improve patient outcomes through research, education, and advocacy Table of Contents President’s Message: How Do I Get Involved with ASRA? ___ 3 Editor Kristopher Schroeder, MD Editor's Message: Help! ____________________________ 5 Newsletter Committee Regional Fellowship-Trained Versus Non-Fellowship Vivian Ip, MB, ChB (Regional Anesthesia Lead) Trained Consultants: Does It Matter? __________________ 7 Dalia Elmofty, MD (Pain Medicine Lead) Veena Graff, MD The Beauty of Diversity in Medicine __________________ 10 Jerry Jones, MD Anthony Machi, MD Leadership Qualities: What Makes a Great Leader? ______ 16 Sudheer Potru, MD John-Paul Pozek, MD Physician Mentorship and Leadership Development Shalini Shah, MD Special Interest Group ____________________________ 20 Reda Tolba, MD James Turner, MD What Showing Up Can Do for You ____________________ 23 Resident Section Chair How I Do It: A Pathway for Total Knee Arthroplasty ______ 25 Reena John, MD Cannabis as an Analgesic: Separating Hope from Foreign Corresponding Hype __________________________________________ 29 Clara Lobo, MD Amit Pawa, MBBS Virtual Reality for Pain Management: A Guide to Clinical Implementation ___________________________ 32 Officers President: Eugene R. Viscusi, MD How I Do It: Stellate Ganglion Blocks _________________ 36 President-Elect: Samer Narouze, MD, PhD Treasurer: David Provenzano, MD Sympathetic Blocks for Postoperative Pain Control Past-President: Asokumar Buvanendran, MD After Surgery: Literature Review and Current Evidence ______________________________________ 39 Board of Directors Steven P. Cohen, MD Surgical Considerations for Spinal Cord Stimulation Nabil M. Elkassabany, MD, MSCE Implant _______________________________________ 41 Sandra L. Kopp, MD Stavros Memtsoudis, MD Radiofrequency Ablation and Its Role in Treating Carlos Pino, MD Chronic Pain ____________________________________ 47 Meg A. Rosenblatt, MD Gina Votta-Velis, MD, PhD Transforming Acute Pain Management in Sickle Cell Disease: Where Are We Now? ______________________ 50 Staff Executive Director: Angie Stengel, MS, CAE Regional Nerve Blockade: What’s the Long Game? ______ 55 Deputy Executive Director/Communications Director: Anne Snively, MBA, CAE Literature Review ________________________________ 57 Communications Coordinator: Athena Ermidis, BA Founding Fathers† L. Donald Bridenbaugh, MD Harold Carron, MD Jordan Katz, MD P. Prithvi Raj, MD Alon P. Winnie, MD †Deceased American Society of Regional Anesthesia and Pain Medicine 3 Penn Center West, Suite 224 • Pittsburgh PA 15276 phone toll free 855-795-ASRA • fax 412-471-7503 • www.asra.com Copyright © 2020 American Society of Regional Anesthesia and Pain Medicine. All rights reserved. ASRA News is published quarterly in February, May, August, and November. ISSN: 2474-2864 2 Contents may not be reproduced without prior written permission of the publisher. President’s Message: How Do I Get Involved with ASRA? If there is one question I am asked more than any other Integrative Medicine SIG, are it is “How do I get involved with ASRA?” As we navigate in discussion. through this extraordinary time, it is more important than ever for our ASRA family to come together. The Regional Anesthesia Whether you are new to ASRA or joined many years ago, & Pain Medicine journal is we encourage you to be an active member of the Society always looking for reviewers. and help shape our future offerings. Peer-reviewers play a critical role in reviewing the science, While nothing can replace a live meeting and human research, accuracy, and clarity interaction, the virtual world has come to the forefront of submitted manuscripts. for engaging with family, friends, and colleagues. The Physicians, PhDs, ASRA Connect online community is a great place to psychologists, and others share your experiences, ask questions, and provide working in the field are invited expert advice. ASRA members can use the Member to participate. To apply, go to Eugene R. Viscusi, MD Directory to connect with colleagues and friends. https://mc.manuscriptcentral. ASRA President When it is time to meet again at the in-person annual com/rapm and create an meetings, be sure to join us at the Welcome Reception, account. Indicate your areas of participate in ASRA Let’s Eat, and celebrate at the expertise using the keywords section. Please reach out Annual Meeting Reception. These connections will to [email protected] or [email protected] with any provide a sense of community for which we are all questions you may have about this process. yearning and looking forward to in the future. The ASRA Committees provide another way to The ASRA Special Interest Groups (SIGs) offer a variety contribute to your Society. If you are concerned with of ways to be involved. Look among the many areas of issues related to regulatory advocacy, guidelines, special interests and consider joining one or more that practice advisories, or standards, volunteer to serve on aligns with your goals and the ASRA Guidelines interests. You will interact and Regulatory with like-minded colleagues "With approximately 40% of Advocacy who wish to move ASRA Committee, or if forward with a special committee appointments being you are interested goal or initiative. The SIG in developing families are always looking members who have never programs, products, for volunteers to serve on and services to their leadership teams and served on an ASRA committee, support the needs help create content. Offer to of new professionals write an article or create a we value the importance of aspiring to be webcast on a topic important faculty and to you. Each SIG has its bringing new thought leaders researchers, own online community in volunteer for the ASRA Connect to share to the table every year." ASRA Faculty successes and challenges Development and exchange resources. With 22 SIGs covering a Committee. ASRA has more than 10 standing variety of topics, there is sure to be a SIG for everyone. committees, which are always looking for new, And, if you can’t find something of interest to you, let innovative committee members to participate. With us know. New SIGs are formed by members actively approximately 40% of committee appointments pursuing and creating what doesn’t already exist. A being members who have never served on an ASRA group of members did just that and established the committee, we value the importance of bringing new Physician Mentorship and Leadership Development thought leaders to the table every year. The Call SIG. Later in this newsletter you will hear about their for ASRA Volunteers is sent each September, with SIG and a new opportunity with the launch of the ASRA committee terms commencing the following spring. Mentor Match Program. Soon we will have a Wellness Please click here to be notified when the nominations SIG, and others, such as a Complementary and process opens. American Society of Regional Anesthesia and Pain Medicine 2020 3 Perhaps the first step is to be visible! Come to a I hope all of you will consider one of the many meeting. Consider submitting an abstract, case report opportunities to get involved, be active, and come or QA/QI project, and be part of the meeting. Identify together. I look forward to working more closely with yourself as someone new or someone interested in many of you in the very near future. After all, we are getting involved. Talk to SIG leaders and express your family, and together we can further our mission of interests. Join a virtual event and participate in the improving patient outcomes through research, education, conversation. ASRA is a wonderful family, one that has and advocacy by sharing our knowledge and expertise. been the highlight of my career. Be well and stay safe! American Society of Regional Anesthesia and Pain Medicine 4 2020 Editor's Message: Help! I'm so tired, I haven't slept a wink level or muster the courage I'm so tired, my mind is on the blink to ask/apply for an academic opportunity, Dr. George “I’m So Tired” – The Beatles. 1968. Arndt (inventor of the Arndt endobronchial blocker and It's been a hard day's night, and I've been working like a dog airway exchange catheter kit) It's been a hard day's night, I should be sleeping like a log was there for me. If I needed But when I get home to you, I'll find the things that you do someone to commiserate or Will make me feel alright collaborate with, I had a peer in Dr. Melanie Donnelly, who “A Hard Day’s Night” – A Hard Day’s Night. 1964. helped me place academic or personal setbacks into Universal truths for medical providers include being perspective. However, I could asked to accomplish too much in too little time. See too not always find everything Kristopher M. Schroeder, MD many patients and assimilate too many new procedures that I needed at the time that Professor and surgical indications into the daily schedule while I needed it within my home University of Wisconsin School teaching the next generation of students/residents and institution. I was therefore of Medicine and Public Health documenting too many procedures in an EMR that may fortunate that there were Madison, Wisconsin not make a bit of sense. At the same time, there is a faculty within ASRA who have ASRA News Editor compelling need to engage in research that advances sacrificed some of themselves the science of our profession and attend to a tapestry of to assist me in my academic administrative responsibilities that are required to keep career. Finding these amazing faculty was not easy but the operating rooms operating.
Load more

Recommended publications
  • Intravenous Therapy Procedure Manual
    INTRAVENOUS THERAPY PROCEDURE MANUAL - 1 - LETTER OF ACCEPTANCE __________________________________________ hereby approves (Facility) the attached Reference Manual as of _____________________. (Date) The Intravenous Therapy Procedure Manual will be reviewed at least annually or more often when deemed appropriate. Revisions will be reviewed as they occur. Current copies of the Intravenous Therapy Procedure Manual shall be maintained at each appropriate nursing station. I have reviewed this manual and agree to its approval. __________________________ (Administrator) __________________________ (Director of Nursing) __________________________ (Medical Director) - 2 - TABLE OF CONTENTS TABLE OF CONTENTS INTRODUCTION A. Purpose 1 B. Local Standard of Practice 1 RESPONSIBILITIES A. Responsibilities: M Chest Pharmacy 1 B. Responsibilities: Administrator 1 C. Responsibilities: Director of Nursing Services (DON/DNS) 1 D. Skills Validation 2 AMENDMENTS GUIDELINES A. Resident Candidacy for IV Therapy 1 B. Excluded IV Medications and Therapies 1 C. Processing the IV Order 1 D. IV Solutions/Medications: Storage 2 E. IV Solutions/Medications: Handling 3 F. IV Solutions and Supplies: Destroying and Returning 4 G. IV Tubing 5 H. Peripheral IV Catheters and Needles 6 I. Central Venous Devices 7 J. Documentation and Monitoring 8 K. IV Medication Administration Times 9 L. Emergency IV Supplies 10 I TABLE OF CONTENTS PROTOCOLS A. IV Antibiotic 1 1. Purpose 2. Guidelines 3. Nursing Responsibilities B. IV Push 2 1. Purpose 2. Guidelines C. Anaphylaxis Allergic Reaction 4 1. Purpose 2. Guidelines 3. Nursing Responsibilities and Interventions 4. Signs and Symptoms of Anaphylaxis 5. Drugs Used to Treat Anaphylaxis 6. Physician Protocol PRACTICE GUIDELINES A. Purpose 1 B. Personnel 1 C. Competencies 1 D.
    [Show full text]
  • Attachment 3
    CURRICULUM CLINICAL BASE / CA-1 / CA-2 / CA-3 ANESTHESIOLOGY RESIDENCY PROGRAM GOALS AND OBJECTIVES AND CORE COMPETENCIES Department of Anesthesiology University of Missouri at Kansas City School of Medicine Saint Luke’s Hospital Truman Medical Center Children’s Mercy Hospital Revised 2011 Table of Contents Pages Introduction – Statement of Curriculum ................................................................................................................... 3 I. Rendering Patient Insensible to Pain ............................................................................................................. 4-10 II. Support of Life Functions ............................................................................................................................. 11-16 III. Clinical Base Year A. Cardiology ................................................................................................................................................. 17-32 B. Emergency Medicine ................................................................................................................................. 33-44 C. General Medicine ....................................................................................................................................... 45-49 D. Infectious Disease ...................................................................................................................................... 50-59 E. Nephrology ..............................................................................................................................................
    [Show full text]
  • Nicotine Patches Appear Safe for CAD Patients
    May 1, 2007 • www.internalmedicinenews.com Cardiovascular Medicine 37 Nicotine Patches Appear Safe for CAD Patients BY BRUCE JANCIN 30%, but many physicians have been re- induced myocardial defect on single-photon ment arm jumped from 10.9 to 25.2 Denver Bureau luctant to recommend it for their patients emission computed tomography (SPECT) ng/mL, Dr. Leja said. After 1 week, patients with coronary artery disease (CAD) be- to receive either 21-mg nicotine patches or were encouraged to quit smoking while N EW O RLEANS — Nicotine patches cause nicotine is known to increase heart placebo in addition to continuing their usu- continuing to use their assigned patches. are safe for use in smokers with known rate and blood pressure, and can induce al amount of cigarette smoking. The pri- Upon SPECT imaging at week 4, the coronary artery disease and stress-induced vasoconstriction as well, Dr. Monika J. Leja mary end point of the study was change in size of the perfusion defects in the nico- myocardial ischemia, according to the re- reported at the annual scientific session of total perfusion defect size upon repeat stress tine patch group remained unchanged sults of the first-ever randomized, place- the American College of Cardiology. SPECT imaging performed at 1 week. from baseline, although their plasma nico- bo-controlled, multicenter clinical trial to Dr. Leja and her coinvestigators at the There was no change in the total or is- tine levels remained as high as at week 1. examine this issue. Methodist DeBakey Heart Center in Hous- chemic perfusion defect size, compared The trial was supported by Glaxo- Nicotine replacement therapy doubles ton randomized 55 heavy smokers with with baseline, in either group even though SmithKline Consumer Healthcare.
    [Show full text]
  • Intravenous Infusion Drug Administration: Flushing Guidance
    Intravenous Infusion Drug Administration: Flushing Guidance April 2019 Acknowledgements: Andrew Barton – Author/reviewer NIVAS Chair Advanced Nurse Practitioner, IV Therapy and Vascular Access Frimley Health NHS Foundation Trust Tim Jackson – Reviewer/contributor, NIVAS Board Deputy Chair Consultant in Anesthesia & Intensive Care Medicine Calderdale & Huddersfield NHS Foundation Trust Gemma Oliver - Reviewer/contributor NIVAS Board Nurse Consultant, Integrated IV Care East Kent Hospitals NHS Foundation Trust Nicola York - Reviewer/contributor NIVAS Board Clinical Nurse Manager Vascular Access and Nutrition support Oxford University Hospitals NHS Foundation Trust Matt Jones - Reviewer/contributor NIVAS Board Consultant Anaesthetist East Kent Hospitals NHS Foundation Trust Steve Hill - Reviewer/contributor NIVAS Board Procedural Team Manger The Christie NHS Foundation Trust Marie Woodley - Reviewer/contributor NIVAS Board Clinical Nurse Specialist IV therapy/OPAT Lead Buckinghamshire Healthcare Trust Contents: Introduction………………………………………………………………………… Page 1 Methods of administering intravenous therapy………………………………… Page 2 Intravenous bolus injection…………………………………………….… Page 2 Continuous, variable dose syringe driver injection……………………. Page 2 Intravenous infusion…………………………………………………….… Page 3 Option 1: Discarding the infusion set………………………………….… Page 3 Option 2: Flushing the Infusion set manually…………………………... Page 4 Option 3: Flushing the infusion set with a closed system…………….. Page 4 General Guidance…………………………………………………………………. Page 5 Conclusion………………………………………………………………………….
    [Show full text]
  • Intravenous Therapytherapy
    IntravenousIntravenous TherapyTherapy Department of EMS Professions Temple College IVIV TherapyTherapy OverviewOverview I DefinitionsDefinitions && IndicationsIndications I FluidFluid ResuscitationResuscitation I EquipmentEquipment andand SuppliesSupplies I ChoosingChoosing FluidsFluids andand CathetersCatheters I ProcedureProcedure andand TechniqueTechnique TipsTips – Peripheral Venipuncture – Intraosseous Access I PotentialPotential ComplicationsComplications DefinitionsDefinitions I IVIV // VenipunctureVenipuncture I CrystalloidsCrystalloids I PeripheralPeripheral // CentralCentral I ColloidsColloids I IntraosseousIntraosseous AccessAccess I HypertonicHypertonic I FluidFluid ResuscitationResuscitation I IsotonicIsotonic I MedicationMedication AccessAccess I DripDrip RatesRates I KVOKVO // TKOTKO IndicationsIndications forfor VenipunctureVenipuncture I VolumeVolume I VenousVenous AccessAccess toto – Dehydration CirculationCirculation I Water – Blood collection I Electrolytes I Labs – Blood Loss I Field Chemistry I Colloids – Medication I Crystalloids Administration FluidFluid ResuscitationResuscitation I DehydrationDehydration andand I ShockShock VolumeVolume LossLoss ManagementManagement – Replace Lost Fluid or – Controversial Blood – Definitive therapy = – Often requires 2 -3 Surgery and blood times the amount replacement lost (2:1 rule) – EMS → judicious replacement – Improve end organ perfusion (BP at 90 - 100 mm Hg) EquipmentEquipment andand SuppliesSupplies I FluidsFluids I SuppliesSupplies – Normal Saline – IV Catheters (0.9%
    [Show full text]
  • Intravenous Medicine Administration Self-Directed Learning Package
    Acute Services Division Practice Development Department Intravenous Medicine Administration Self-directed Learning Package Margaret A. Connolly Katherine Hill Lynne Robertson Debbie Thompson Pinky Virhia First published August 2007 Revised July 2014 For review July 2016 Contribution by Christina Ronyane © Practice Development Department, NHS Greater Glasgow and Clyde 2014. All rights reserved. No part of this document may be reproduced, stored in a retrieval system or transmitted in any form or by any means electronic, mechanical, photocopying,recording or otherwise without the prior permission of Practice Development Department, NHS GG&C. Acknowledgement of sources of illustrations Figure 1 – page 7 Yellow Card Reproduced with the kind permission of the MHRA. Figure 2 – page 9 Peripheral venous access. Reproduced with the kind permission of Smith and Nephew. Figure 3 – page 10 Midline. Images provided by Vygon (UK) Ltd – © Vygon (UK) Ltd 2012. Figure 4 – page 10 Peripherally inserted central catheter. Provided by Vygon (UK) Ltd - © Vygon (UK) Ltd 2012. Figure 5 – page 10 Non Skin Tunnelled Central Line. Reproduced with the kind permission of Smith and Nephew. Figure 6 – page 11 Skin Tunnelled central venous access. Provided by Vygon (UK) Ltd - © Vygon (UK) Ltd 2012. Figure 7 – page 11 Indwelling Central Venous Access Device. Provided by Vygon (UK) Ltd - © Vygon (UK) Ltd 2012. Figure 10 – page 19 Anaphylaxis algorithm - Reproduced with the kind permission of the Resuscitation Council (UK). Contents Prerequisites for undertaking the IV
    [Show full text]
  • Improvement of Biodistribution with Pegylated Liposomes Containing
    ANTICANCER RESEARCH 31: 153-160 (2011) Improvement of Biodistribution with PEGylated Liposomes Containing Docetaxel with Degradable Starch Microspheres for Hepatic Arterial Infusion in the Treatment of Liver Metastases: A Study in CC-531 Liver Tumor-bearing WAG RIJ Rats U. POHLEN, H.J. BUHR and G. BERGER Department of Surgery, Charité Universitaetsmedizin Berlin, Benjamin Franklin Campus, Berlin, Germany Abstract. Aim: To improve the drug concentration in liver metastatic breast cancer develop liver metastases and have a metastases, docetaxel was encapsulated in polyethyleneglycol- poor prognosis, with a median survival of 1-2 years and a 5- liposomes and administered regionally with degradable starch year survival rate of approximately 20% (6, 7). microspheres (DSM). Materials and Methods: A rodent model The most frequently applied chemotherapeutic agent for of solitary metastasis (CC-531 adenocarcinoma) was studied. advanced breast cancer, ovarian cancer and gastric cancer is The animals were randomized into six groups and treated with docetaxel (8-10). 15 ng/kg docetaxel: I: intravenous (i.v.). II: PEG-liposomes Docetaxel inhibits cell proliferation by inducing a i.v.; III: intraartial (i.a.) via the hepatica artery; IV: i.a.) + sustained mitotic block at the metaphase/anaphase anticancer DSM; V: PEG-liposomes i.a.; and VI: PEG-liposomes i.a. + agents in this class promote the polymerization of stable DSM. The docetaxel concentration in the serum, liver and liver microtubules, inhibit their disassembly and profoundly affect tumor at defined times (5, 15, 30, 60,120 240 min and 24 h) a number of key cellular functions that depend on the was measured using HPLC.
    [Show full text]
  • Improving Intravenous Therapy: Opportunities for Designing the Next Generation Infusion System Part 3 – Workflow Efficiency & Cost-Effectiveness
    IMPROVING INTRAVENOUS THERAPY: OPPORTUNITIES FOR DESIGNING THE NEXT GENERATION INFUSION SYSTEM PART 3 – WORKFLOW EFFICIENCY & COST-EFFECTIVENESS AUTHORED BY: Matthew B. Weinger, MD, MS Andrew Kline, BA Department of Anesthesiology, Vanderbilt University School of Medicine INTRODUCTION In this three-part series, we strive to provide an overview of the current status and apparent effectiveness from the user’s point- of-view of infusion pump design. We acknowledge the advances in the field while highlighting opportunities for future improvements. In focusing on some of the usability issues of current pump interfaces and insufficient interoperability, we highlight some of the existing pitfalls and offer human factors-based guidance for next-generation designs. Here, we define infusion pump usability as the relationship We focus on issues related to the between the technology and clinicians’ ability to use that technology general usability, process efficiency and to attain their work goals effectively, safely, efficiently, and with both clinician and patient satisfaction. cost effectiveness of infusion pump use. In this, the third part of the series, we focus on issues related to the general usability, process efficiency and cost effectiveness of infusion pump use. We also address current shortcomings of the integration of infusion pump technology with medication management software. 1 Workflow Efficiency and Cost Effectiveness An important added benefit of optimal pump designs is the prospect of significant cost savings. Each preventable ADE has been reported to cost nearly $9,000,[1] and smart pumps could, through built-in designs to adhere to the “Rights,” decrease the incidence of ADEs (see Part 1 of this series for more information on this topic).
    [Show full text]
  • Intravenous Therapy
    Intravenous therapy What is an intravenous? An intravenous is a thin, plastic tube called a catheter that is put into a vein to give you fluid. The catheter is attached to a solution bag hanging on a pole. This is all called an IV. The type of solution you have depends on your special needs. The IV needs to go into a vein so the blood can carry the fluid around your body. Most often, the IV is put in your hand or forearm. An IV can be put in a foot, upper arm or inner elbow. You may have an IV lock called a saline lock. This means that the catheter is attached to a very short tube with a cap. When it is time for fluid or medication, the cap is taken off and the catheter is attached to a longer tube and solution. This is most often done if you need an IV for medications but do not need extra fluid. Why do I need an IV? There are many reasons for having an IV. Here are some reasons: to give fluids to give medication to give blood or blood products please turn over Intravenous therapy What is an IV pump? Your IV may be connected to an IV pump. The nurses program the pump to deliver the right amount of medications and fluids. It will beep or alarm for different reasons. What activities can I do with an IV? After the IV is put in, there is no needle left in your vein. The tube is held in your vein with tape.
    [Show full text]
  • (Not for IV Bolus Injection) RX ONLY ERAXIS™ (Anidulafungin
    NDA 21-632/S-010 Page 6 [INTRAVENOUS INFUSION, DILUTED WITH STERILE WATER FOR INJECTION] (not for IV Bolus Injection) RX ONLY ERAXIS™ (anidulafungin) FOR INJECTION DESCRIPTION ERAXIS for Injection is a sterile, lyophilized product for intravenous (IV) infusion that contains anidulafungin. ERAXIS (anidulafungin) is a semi-synthetic lipopeptide synthesized from a fermentation product of Aspergillus nidulans. Anidulafungin is an echinocandin, a class of antifungal drugs that inhibits the synthesis of 1,3-β-D-glucan, an essential component of fungal cell walls. ERAXIS (anidulafungin) is 1-[(4R,5R)-4,5-Dihydroxy-N2-[[4"-(pentyloxy)[1,1':4',1"-terphenyl]-4­ yl]carbonyl]-L-ornithine]echinocandin B. Anidulafungin is a white to off-white powder that is practically insoluble in water and slightly soluble in ethanol. In addition to the active ingredient, anidulafungin, ERAXIS for Injection contains the following inactive ingredients: 50 mg/vial - fructose (50 mg), mannitol (250 mg), polysorbate 80 (125 mg), tartaric acid (5.6 mg), and sodium hydroxide and/or hydrochloric acid for pH adjustment. 100 mg/vial - fructose (100 mg), mannitol (500 mg), polysorbate 80 (250 mg), tartaric acid (11.2 mg), and sodium hydroxide and/or hydrochloric acid for pH adjustment. The empirical formula of anidulafungin is C58H73N7O17 and the formula weight is 1140.3. The structural formula is: H H OH O HO OC5H11 H O NH HO NH O H C H 3 HN CH N 3 H O H HO O H OH H NH N H3C H H OH HO N O H H H O OH H H OH Prior to administration, ERAXIS for Injection requires reconstitution with sterile Water for Injection and subsequent dilution with either 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP (normal saline).
    [Show full text]
  • IV Infusion Therapy Forms
    Intravenous (IV) Infusion Therapy Checklist of what to bring: Your completed Intravenous (IV) Therapy Intake Form A copy of your most recent bloodwork (including G6PD) is helpful Your signed Consent Form Make sure that you are well hydrated prior to your visit; we suggest drinking one to two 16oz. bottles of water. Dehydration can make it difficult to insert an IV. Make sure you eat something prior to you visit; we suggest a high protein snack, such as nuts, seeds, a protein bar, cheese, yogurt, or eggs. Low blood sugar can make you feel weak, light-headed, or dizzy. During your first visit for IV Therapy infusions: During the first visit, the healthcare practitioner will discuss your symptoms and desired outcomes. Based on this assessment, your IV infusion will be customized to address your needs. If you have any complex medical conditions, the healthcare practitioner may request that you obtain blood work and/or your PCP’s approval prior to administering any IV infusions. What to eXpect: The IVs used during your Intravenous (IV) infusion therapy are eXactly the same that you would find in a hospital. Instead of a clinical eXperience though, our IV infusions are given in a peaceful spa setting and leave you feeling calm, relaXed, and refreshed. Depending on your customized IV cocktail, the infusion can be finished in as little as 20- 30 minutes. Our friendly and attentive staff will keep you calm, cared for, and comfortable during your infusion. Patients find the eXperience tranquil and healing. Patients leave feeling vibrant, energized, and refreshed. Flatiron Functional Medicine 400 S.
    [Show full text]
  • Home Health Care (For Nebraska Only) – Community Plan Coverage
    UnitedHealthcare® Community Plan Coverage Determination Guideline Home Health Care (for Nebraska Only) Guideline Number: CS137NE.O Effective Date: July 1, 2021 Instructions for Use Table of Contents Page Related Community Plan Policies Application ..................................................................................... 1 • Home Hemodialysis (for Nebraska Only) Coverage Rationale ....................................................................... 1 • Private Duty Nursing (PDN) Services (for Nebraska Definitions ...................................................................................... 2 Only) Applicable Codes .......................................................................... 3 • Skilled Care and Custodial Care Services (for References ................................................................................... 11 Nebraska Only) Guideline History/Revision Information ..................................... 11 Instructions for Use ..................................................................... 11 Commercial Policy • Home Health Care Medicare Advantage Coverage Summary • Home Health Services and Home Health Visits Application This Coverage Determination Guideline only applies to the state of Nebraska. Coverage Rationale Indications for Coverage The services being requested must meet all of the following criteria: A written treatment plan must be submitted with the request for specific services and supplies. Periodic review of the written treatment plan may be required for continued Skilled
    [Show full text]